{"id":"eca1b6e7-fa2a-4671-960b-be5214051e26","arxiv_id":"2608.07865","paper_version":1,"verdict":"CONDITIONAL","confidence":"HIGH","novelty_score":7.0,"correctness_risk":"medium","formal_verification":"none","parameter_count":0,"one_line_summary":"In IDH-wildtype glioblastoma, higher MAPK pathway activity reproducibly associates with lower PPOX expression, relocating the proposed mechanism of reduced 5-ALA fluorescence from clearance to synthesis.","lead":"This study re-analyzed two independent glioblastoma gene-expression datasets and found that higher MAPK pathway activity consistently tracks with lower expression of PPOX, an enzyme that produces the fluorescent molecule used in 5-ALA guided surgery. The finding shifts the proposed mechanism from PpIX clearance to PpIX synthesis and suggests MEK inhibitors might boost tumor fluorescence, though the link remains correlational.","discovery_kind":"new_application","skeptic_critique":{"model":"deepseek-v4-flash","headline":"The replicated mRNA-level MPAS–PPOX association is statistically well supported, but the paper's mechanistic repositioning to the synthesis step rests on an unconfirmed transcript-to-protein link that the CPTAC protein data do not yet validate.","rationale":"The reader's weakest assumption correctly identifies the transcript-to-function link as the load-bearing condition for the paper's mechanistic interpretation. The statistical finding of a reproducible negative MPAS-PPOX mRNA correlation is well supported: it replicates across two independent cohorts, survives permutation testing, bootstrap resampling, alternative purity-adjustment schemes, and an orthogonal ssGSEA-based MAPK measure. My stress-test does not challenge those statistics. What would have to be true for the paper's broader claim to hold is that lower PPOX mRNA leads to lower PPOX protein/activity and thus lower PpIX synthesis and fluorescence. The only protein-level evidence (CPTAC, Section 6.4) shows a non-significant trend in the same direction, with the paper itself reporting that mRNA-protein discordance has been observed in this pathway. This is not a fatal flaw because the paper consistently qualifies the result as hypothesis-generating and 'best-supported hypothesis, not an established mechanism.' The reader's CONDITIONAL verdict is therefore appropriate: the central transcript-level claim can be accepted while the mechanistic interpretation awaits protein/functional validation. I recommend no change to the reader's verdict, as the concern is already reflected in the conditional acceptance. My concrete test would resolve the outstanding question by testing the mRNA-protein link with adequate power.","tokens_in":14563,"tokens_out":11144,"duration_ms":131761,"concrete_test":"In an independent or expanded GBM proteogenomic cohort with matched RNA-seq and mass-spectrometry (e.g., CPTAC-3 GBM or a similarly powered cohort), compute the purity-adjusted partial Spearman correlation between the transcriptomic MPAS and PPOX protein abundance, with adequate sample size to detect rho≈-0.25. If the protein-level association remains non-significant or absent, the transcript-to-function assumption underpinning the mechanistic conclusion is unsupported and the paper should be accepted only as a hypothesis-generating transcript-level report, not as evidence for the synthesis-step mechanism.","verdict_should_be":"UNCHANGED","load_bearing_attack":"The paper's central contribution is not merely a correlation of two RNA measurements, but the claim that MAPK activity regulates PpIX at the synthetic step (PPOX) rather than at the clearance steps (ABCB1/FECH). That mechanistic relocation depends on the assumption that PPOX transcript abundance, after purity adjustment, is a valid proxy for functional PPOX enzyme activity controlling PpIX production. The strongest available protein-level test, CPTAC-GBM (n=99), showed the same direction but was not significant (rho=-0.13, 95% CI [-0.32, 0.07], p=0.21; Section 6.4). The paper itself acknowledges this and frames the synthesis-based explanation as a hypothesis. However, the abstract concludes by 'identifying the MAPK pathway as a candidate handle for increasing 5-ALA fluorescence', which is only warranted if the transcript-level association propagates to protein and function. Section 6.4 also cites a study where fluorescence tracked PPOX protein, not mRNA, further emphasising that mRNA is an unvalidated proxy. Without a confirmed transcript-to-protein link, the replicated correlation could be biologically inert or could reflect a different mechanism (e.g., broad metabolic transcriptional programs, as Section 6.1 notes). The statistical claim per se is robust; the load-bearing gap is the missing functional confirmation.","agreement_with_reader":"agree"},"referee_report":{"model":"deepseek-v4-flash","summary":"The manuscript tests, in two independent IDH-wildtype glioblastoma cohorts (TCGA-GBM, n=140; CGGA, n=87), whether MAPK/ERK pathway activity—quantified by the externally developed MPAS transcriptional score and cross-checked with ssGSEA of HALLMARK_KRAS_SIGNALING_UP—correlates with expression of heme-biosynthesis and PpIX-processing genes, with tumor purity as a covariate. Against the cell-line hypothesis that MAPK upregulates ABCB1 and FECH, neither effector replicated across cohorts (ABCB1 null in both; FECH positive only in CGGA, rho=0.28, q=0.0342). The only gene meeting the stated replication criterion (concordant direction, BH q<0.05 in both cohorts) was PPOX: purity-adjusted partial Spearman rho=-0.40 (95% CI [-0.54,-0.25], q<0.001) in TCGA and rho=-0.28 (95% CI [-0.47,-0.07], q=0.0342) in CGGA. Robustness checks include bootstrap CIs, permutation tests, alternative purity metrics, and leave-one-gene-out MPAS recalculation. The authors interpret the finding as relocating the MAPK–PpIX association from clearance to synthesis, note that the CPTAC protein-level check is directionally consistent but non-significant (rho=-0.13, p=0.21), and propose MAPK/MEK inhibition as a candidate handle for increasing 5-ALA fluorescence.","tokens_in":14819,"tokens_out":11286,"duration_ms":120834,"significance":"If the correlational result is taken at face value, this is a useful, well-controlled replicated observation in a clinically relevant setting. The statistical design is strong: independent cohorts, a symmetric replication criterion, bootstrap and permutation checks, purity adjustment, an orthogonal pathway score, and explicit reporting of non-replicating genes. No fitted parameters are introduced, and the authors are unusually candid about limitations. The main reservation is that the translational/mechanistic label ('handle for increasing 5-ALA fluorescence') goes beyond the transcript-level evidence; the CPTAC protein result is non-significant, and the paper itself cites evidence that fluorescence follows PPOX protein rather than mRNA. As a hypothesis-generating finding with clear functional next steps, the paper is valuable; as a mechanistic conclusion, it needs tempering or additional protein/functional validation.","major_comments":[{"comment":"The Abstract's closing claim that the analysis identifies the MAPK pathway as 'a candidate handle for increasing 5-ALA fluorescence' and Section 7's statement that the results 'support the hypothesis that increased MAPK activity lowers tumor fluorescence' go beyond what the transcript-level data can establish. Section 6.4 reports that the CPTAC-GBM protein-level correlation is non-significant (rho=-0.13, 95% CI [-0.32,0.07], p=0.21) and cites Ref. [9] showing that fluorescence tracks PPOX protein rather than mRNA. Since the translational handle depends on transcript-to-protein-to-function propagation, the Abstract and Section 7 should either present this as a hypothesis requiring functional validation or remove the claim.","section":"Abstract / Section 7"},{"comment":"The ssGSEA cross-check is presented as an independent confirmation, but the text does not state whether these correlations are purity-adjusted partial Spearman statistics (as in the primary analysis) or unadjusted Spearman correlations. If unadjusted, the cross-check does not address the primary purity-adjusted claim; if adjusted, the method should be stated. Please clarify and, if necessary, report the purity-adjusted values.","section":"Section 5.3"},{"comment":"The discussion acknowledges that the PPOX association is compatible with MPAS being broadly anti-correlated with metabolic and biosynthetic transcription and that a genome-wide comparison or proliferation-signature adjustment is needed to establish specificity. This is a load-bearing caveat for the paper's framing of PPOX as the uniquely replicated node and for the mechanistic relocation to synthesis. The manuscript should either add such an analysis or explicitly restrict the conclusion to the pre-specified heme panel and state in the Abstract that specificity beyond the panel is not established.","section":"Section 6.1"}],"minor_comments":[{"comment":"There is a typo in the Abstract: 'withPPOX' should be 'with PPOX'.","section":"Abstract"},{"comment":"The software name in Reference [22] is printed as 'GSV A'; it should be 'GSVA'.","section":"Reference [22]"},{"comment":"The sentence reporting 'all p <0.05 after Benjamini–Hochberg correction' across the seven purity-adjustment scenarios is ambiguous: please clarify whether the correction is applied within each scenario or across the scenario tests, and report the corrected values consistently.","section":"Section 5.4"},{"comment":"Please state explicitly whether the CPTAC-GBM analysis uses MPAS computed from matched RNA-seq and PPOX protein from mass spectrometry, and whether the reported rho is an unadjusted or purity-adjusted partial correlation; the current text calls it an 'unadjusted proteomic analysis' but does not define the statistic.","section":"Section 6.4"},{"comment":"The statement that code and results are 'available from the author upon reasonable request' is not a reproducible-availability standard; please deposit the code and processed data in a public repository with a persistent identifier.","section":"Code and Data Availability"},{"comment":"The quality-control exclusion based on RN7SL2 accounting for more than 20% of reads is not cited or justified; please provide a reference or a rationale for this threshold.","section":"Section 3.2"},{"comment":"The Neural subtype has n=6 and is described as underpowered in the text; please include this caveat in the Figure 4 caption as well, so the figure is not read without the sample-size warning.","section":"Section 5.5"}],"recommendation":"major_revision","confidential_remarks":"The statistical core is solid and the paper is honest about limitations, so I would not reject it. My main concern is that the Abstract and contribution statements overstate the mechanistic and translational implications relative to the transcript-level evidence; this can be fixed by rewriting and possibly by adding a genome-wide control for the PPOX specificity claim. The use of 'pre-specified' without a dated analysis plan should also be clarified in revision. The paper is appropriate for q-bio.GN if framed as hypothesis-generating."},"author_rebuttal":null,"desk_editor":{"model":"deepseek-v4-flash","letter":"You should know this paper is worth a serious look. The new thing is the first replicated human-tissue test of the cell-line MAPK–PpIX mechanism, and it lands on PPOX, the synthesis enzyme, not the ABCB1/FECH clearance effectors. That is a genuinely novel empirical result, not a restatement of prior work. The two-cohort design with a pre-specified replication criterion (concordant direction, BH q<0.05) is exactly the right discipline for this kind of transcriptomic fishing, and the robustness work is thorough: bootstrap CIs, permutation tests, alternative purity metrics, leave-one-gene-out sensitivity, and an orthogonal ssGSEA cross-check. The paper is also unusually honest about its limits, which makes the overreach in the abstract more irritating than damning.\n\nThe soft spots are real but not fatal. The biggest is the transcript-to-function gap. The CPTAC proteomic cohort shows the same direction but does not reach significance (rho=-0.13, p=0.21), and the abstract's closing claim that MAPK is a \"candidate handle for increasing 5-ALA fluorescence\" goes beyond what a transcript-level correlation supports. To the authors' credit, Section 6.1 and 6.4 flag this clearly, but the abstract does not. Second, the code is only \"available upon request,\" which in practice means not reproducible without emailing the author; that should be fixed before publication. Third, there is no genome-wide control for whether the PPOX association is specific or just one instance of a broader metabolic program; the authors acknowledge this, but it remains an open question. Fourth, the direction of effect is not settled: PPOX inhibition can paradoxically raise PpIX via protoporphyrinogen IX leakage, so even if the association is causal, the fluorescence consequence is not guaranteed.\n\nNone of these undermine the central correlational claim, which is statistically well supported. The paper deserves a proper referee: the discovery-validation logic is sound, the analysis is careful, and the finding is new enough to merit confirmation attempts. I would recommend acceptance after minor-to-moderate revision, requiring code deposition, softening the abstract to match the hypothesis-generating tone of the discussion, and ideally adding a genome-wide correlation scan or a proliferation-signature adjustment to strengthen specificity. Bring it to reading group if you want a concrete example of how to do replication-right in bulk transcriptomics.","headline":"A clean replicated correlational result that usefully relocates the MAPK–PpIX link from clearance to synthesis, but the mechanistic framing outruns the protein-level evidence.","tokens_in":15337,"tokens_out":1359,"would_cite":true,"duration_ms":17313,"reading_group":"yes","serious_thinker":"yes","would_accept_peer_review":true},"rs_alignment":null,"lean_confirmation":null,"pith_extraction":{"msc":[],"pacs":[],"model":"deepseek-v4-flash","headline":"In IDH-wildtype glioblastoma, MAPK pathway activity is reproducibly associated with lower expression of PPOX, the enzyme that synthesizes the fluorescent molecule protoporphyrin IX, in two independent, purity-adjusted cohorts.","keywords":["Glioblastoma","5-aminolevulinic acid","protoporphyrin IX","fluorescence-guided surgery","MAPK signaling pathway","heme biosynthesis","protoporphyrinogen oxidase","tumor purity adjustment"],"falsifier":"Measure PpIX fluorescence or PpIX abundance directly in IDH-wildtype glioblastoma samples stratified by MAPK activity and PPOX expression. If high-MAPK tumors with low PPOX messenger RNA do not show lower PpIX than low-MAPK tumors, the claimed synthesis-locus mechanism fails; similarly, if manipulating PPOX expression changes messenger RNA but not PpIX production, the transcript-to-function bridge breaks.","tokens_in":14366,"feed_emoji":"🧬","tokens_out":10054,"duration_ms":92555,"temperature":0.7,"pith_summary":"Using two independent, purity-adjusted sets of primary IDH-wildtype glioblastoma specimens, this paper tests whether the MAPK signaling pathway controls the fluorescent molecule protoporphyrin IX (PpIX) in human tissue the way cell-culture studies say it does. It finds that the two clearance-related effectors proposed by the cell-line model, ABCB1 and FECH, do not reproduce across both cohorts. Instead, MAPK pathway activity is consistently associated with lower expression of PPOX, the enzyme that makes PpIX in the final synthetic step, in both cohorts. The paper reads this as relocating the likely regulatory point from PpIX removal to PpIX synthesis, and as identifying MEK/MAPK inhibition as a candidate lever for making 5-ALA-guided surgery fluorescence more reliably. This matters because the prior mechanism had never been confirmed in whole human tumors.","feed_headline":"MAPK activity links to lower PPOX in two GBM cohorts","feed_subtitle":"The inverse link replicates in two cohorts, shifting the 5-ALA fluorescence story to heme synthesis, not clearance.","key_machinery":"The central object is PPOX, protoporphyrinogen oxidase, the enzyme that oxidizes protoporphyrinogen IX into the fluorescent PpIX; its transcript abundance is the outcome variable. The pathway instrument is a ten-gene transcriptional activity score averaged per cohort (its constituent targets: DUSP4, DUSP6, ETV4, ETV5, PHLDA1, SPRY2, SPRY4, CCND1, EPHA2, EPHA4), and the load-bearing statistic is the purity-adjusted partial rank correlation, with false-discovery-rate correction applied across the gene panel within each cohort. Replication is defined prospectively as reaching the adjusted threshold in both cohorts with the same direction; only PPOX meets it. Because the two expression matrices are analyzed separately, the cross-cohort agreement is the validation.","core_discovery":"The central discovery, on the paper's own terms, is a reproducible inverse association between MAPK pathway activity and PPOX transcript expression in IDH-wildtype glioblastoma. The association appears in both cohorts after purity adjustment: discovery rho = -0.40 with bootstrap 95% CI [-0.54,-0.25] and adjusted p < 0.001; validation rho = -0.28 with 95% CI [-0.47,-0.07] and adjusted p = 0.0342. It survives permutation testing, bootstrap resampling, alternative purity-adjustment schemes, and re-scoring of the pathway activity measure with each of its ten constituent genes removed one at a time. The effectors the cell-line model predicted, ABCB1 and FECH, do not hold to the same replicated standard, with FECH significant in one cohort only and ABCB1 in neither. The paper concludes that if the correlation is causal, MAPK controls PpIX at the synthetic step through PPOX, and that this relationship is biological rather than prognostic.","pith_inferences":["I infer the decisive untested experiment is direct measurement of PpIX accumulation in tumors stratified by MAPK activity and PPOX expression; without it, lower PPOX transcript could reflect a broad anti-biosynthetic program rather than a specific control of fluorescence.","The protein-level result in the paper's exploratory cohort ran in the same direction but did not reach significance, so a larger matched proteomic study would test whether the transcript-level signal survives translation to functional enzyme.","A natural follow-up is to ask whether ETS-family or AP-1 transcription factors, the usual MAPK effectors, bind and regulate the PPOX promoter; the paper leaves that open.","Because another heme-pathway gene showed an equally strong correlation in the discovery cohort, a genome-wide correlation screen would test whether the PPOX association is specific to heme synthesis or one instance of MAPK anti-correlating broadly with metabolic transcription."],"forward_implications":["If the correlation is causal, suppressing MAPK signaling becomes a testable route to raise 5-ALA fluorescence, because the reproducible control point is the synthesis step rather than the efflux or conversion step.","The cell-line-predicted effectors ABCB1 and FECH do not meet the same replication standard, so candidate lists from cell culture should be narrowed before clinical targeting.","The absence of a survival association means MAPK pathway status is not supported as a prognostic marker; its relevance, if any, is to fluorescence rather than outcome.","The association's robustness to leaving out each of the ten score genes one at a time and to alternative purity-adjustment schemes indicates it is not an artifact of a single pathway gene or a particular purity metric.","Since PPOX expression does not differ across transcriptional subtypes while MAPK activity does, the continuous MAPK-PPOX association is not a byproduct of subtype grouping."],"supporting_citations":[{"why":"Supplies the cell-line mechanistic model and the effector predictions (ABCB1, FECH) that the study tests in human tissue.","marker":"[6]"},{"why":"Supplies the ten-gene transcriptional pathway activity score used as the primary measure of MAPK activity.","marker":"[19]"},{"why":"Supplies the single-sample gene-set enrichment method used as an orthogonal cross-check of pathway activity.","marker":"[20]"},{"why":"Supplies the hallmark gene set used in the alternative pathway-activity measure for the robustness analysis.","marker":"[21]"},{"why":"Supplies the software implementation used to compute the gene-set enrichment scores.","marker":"[22]"},{"why":"Supplies the independent validation expression cohort.","marker":"[23]"},{"why":"Supplies tumor-purity estimates and molecular subtype calls for the discovery cohort.","marker":"[25]"},{"why":"Supplies the purity-estimation method used for the validation cohort.","marker":"[16]"},{"why":"Supplies the partial-correlation method used for purity-adjusted association tests.","marker":"[27]"},{"why":"Supplies the false-discovery-rate correction applied across the gene panel.","marker":"[28]"}],"fun_headline_variants":["MAPK–PPOX inverse link replicated in two GBM cohorts","MAPK activity tied to lower PPOX, not clearance, in GBM","MAPK–PPOX association flips 5-ALA mechanism to synthesis","GBM: MAPK activity inversely tracks PPOX expression"],"cache_read_input_tokens":3200,"weakest_assumption_plain":"The central assumption is that PPOX messenger-RNA abundance in bulk tumor tissue, after adjusting for tumor purity, faithfully reflects how much functional PPOX enzyme the tumor cells make, and therefore how much fluorescent PpIX they can synthesize.","fun_headline_variants_meta":{"raw":{"variants":["MAPK–PPOX inverse link replicated in two GBM cohorts","MAPK activity tied to lower PPOX, not clearance, in GBM","MAPK–PPOX association flips 5-ALA mechanism to synthesis","GBM: MAPK activity inversely tracks PPOX expression"]},"model":"deepseek-v4-flash","effort":"low","cost_usd":0.000212,"raw_usage":{"total_tokens":1539,"prompt_tokens":1185,"completion_tokens":354,"prompt_tokens_details":{"cached_tokens":384},"prompt_cache_hit_tokens":384,"prompt_cache_miss_tokens":801,"completion_tokens_details":{"reasoning_tokens":275}},"tokens_in":801,"tokens_out":354,"duration_ms":4512,"temperature":1.0,"reasoning_tokens":275,"cache_read_input_tokens":384,"cache_creation_input_tokens":0},"cache_creation_input_tokens":0},"created_at":"2026-08-12T00:44:55.136946+00:00","model_set":{"reader":"deepseek-v4-flash"},"falsifier":"Measure PpIX fluorescence or PpIX abundance directly in IDH-wildtype glioblastoma samples stratified by MAPK activity and PPOX expression. If high-MAPK tumors with low PPOX messenger RNA do not show lower PpIX than low-MAPK tumors, the claimed synthesis-locus mechanism fails; similarly, if manipulating PPOX expression changes messenger RNA but not PpIX production, the transcript-to-function bridge breaks.","supporting_citations":[{"cited_title":"MEK reduces cancer-specific PpIX accumulation through the RSK- ABCB1 and HIF-1α-FECH axes.Scientific Reports, 10(1):22124, December 2020","cited_arxiv_id":null,"evidence_quote":"Supplies the cell-line mechanistic model and the effector predictions (ABCB1, FECH) that the study tests in human tissue."},{"cited_title":"A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types.npj Precision Oncology, 2(1):7, March 2018","cited_arxiv_id":null,"evidence_quote":"Supplies the ten-gene transcriptional pathway activity score used as the primary measure of MAPK activity."},{"cited_title":"Mesirov, and Pablo Tamayo","cited_arxiv_id":null,"evidence_quote":"Supplies the hallmark gene set used in the alternative pathway-activity measure for the robustness analysis."},{"cited_title":"GSV A: gene set variation analysis for microarray and RNA-Seq data.BMC Bioinformatics, 14(1):7, December 2013","cited_arxiv_id":null,"evidence_quote":"Supplies the software implementation used to compute the gene-set enrichment scores."},{"cited_title":null,"cited_arxiv_id":null,"evidence_quote":"Supplies the independent validation expression cohort."},{"cited_title":"Inferring tumour purity and stromal and immune cell admixture from expression data.Nature Communications, 4(1):2612, October 2013","cited_arxiv_id":null,"evidence_quote":"Supplies the purity-estimation method used for the validation cohort."},{"cited_title":"ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients","cited_arxiv_id":null,"evidence_quote":"Supplies the partial-correlation method used for purity-adjusted association tests."}],"review_version":1}